How TET2 changes affect leukemia cells and the bone marrow environment
TET2-mediated epitranscriptomic regulation in leukemia microenvironment
This project looks at how changes in the TET2 enzyme alter RNA and bone marrow signals in people with TET2-deficient acute myeloid leukemia to point toward new treatment targets.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11161595 on NIH RePORTER |
What this research studies
This research focuses on how losing the TET2 enzyme changes chemical marks on RNA and the signals that help leukemia stem cells home to and survive in the bone marrow. Researchers will study patient leukemia samples alongside cell and mouse models to map RNA m5C changes and the Tspan13–CXCR4 signaling pathway. They will test whether blocking those signals reduces leukemia cell migration and self-renewal, with the aim of identifying new targets for therapies.
Who could benefit from this research
Good fit: Patients with acute myeloid leukemia who have TET2 mutations or deletions and who can provide tumor or blood samples for research would be the most relevant candidates.
Not a fit: Patients without TET2 alterations or those seeking immediate clinical treatment are unlikely to get direct benefit from this basic/translational research.
Why it matters
Potential benefit: If successful, the work could reveal new molecular targets that lead to treatments improving outcomes for patients with TET2-mutant AML.
How similar studies have performed: Prior studies have established TET2's role in DNA methylation in AML, but using its RNA demethylation function to target leukemia homing is a newer idea with limited prior clinical testing.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Chen, Jianjun — Beckman Research Institute/city of Hope
- Study coordinator: Chen, Jianjun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.